Notice of Amendment: Revision of Brimonidine on the Prescription Drug List (PDL)
The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing of "brimonidine or its salts" on the Prescription Drug List (PDL). Note that both the human and veterinary parts of the PDL were revised with the addition of a qualifier.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
-
Notice of Amendment: Revision of Brimonidine on the Prescription Drug List (PDL)HTMLEnglish publication HTML
-
Notice of Amendment: Revision of Brimonidine on the Prescription Drug List (PDL)HTMLFrench publication HTML
Similar records